2. Search Result
Search Result
Results for "

GABA-ergics

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Fluorescent Dyes

3

Peptides

3

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0122
    Topiramate
    Maximum Cited Publications
    9 Publications Verification

    McN 4853; RWJ 17021

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate
  • HY-107601
    UBP316

    ACET

    		 iGluR Neurological Disease
    UBP316 (ACET) is a highly potent and selective kainate receptor GluK1 (GluR5) antagonist, with a Kb value of 1.4 nM. UBP316 is effective at blocking the depression of both field excitatory postsynaptic potentials (fEPSPs) and monosynaptically-evoked GABAergic transmission induced by ATPA, a GluK1 selective agonist .
    UBP316
  • HY-B1229
    Isovaleramide
    1 Publications Verification

    3-Methylbutanamide

    		 GABA Receptor Neurological Disease Metabolic Disease
    Isovaleramide (3-Methylbutanamide) is an orally active anticonvulsant. Isovaleramide inhibits alcohol dehydrogenase (ADH) activity and regulates GABAergic system. Isovaleramide reduces acute kidney injury. Isovaleramide has antiepileptic, anxiolytic, sedative and hypnotic effects[1] .
    Isovaleramide
  • HY-16579
    Etifoxine hydrochloride
    3 Publications Verification

    HOE 36-801 hydrochloride

    		 GABA Receptor Neurological Disease
    Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine hydrochloride
  • HY-103504
    (S)-SNAP5114
    1 Publications Verification

    		 GABA Receptor Neurological Disease
    (S)-SNAP5114 is a non-covalent murine GABA transporter inhibitor with blood-brain barrier penetration ability, which exhibits significant subtype-selective inhibitory activity against mGAT4 (pIC50=5.71, pKi=4.56), much higher than its effects on mGAT1, mGAT2 and mGAT3. (S)-SNAP5114 elevates extracellular GABA concentrations by blocking the GABA reuptake mechanism, thereby enhancing thalamus-specific GABAergic signaling and exerting potential neuromodulatory effects. (S)-SNAP5114 is widely used in studies related to epilepsy, neuropathic pain, anxiety and depression, and various neurodegenerative diseases .
    (S)-SNAP5114
  • HY-16579A
    Etifoxine
    3 Publications Verification

    HOE 36-801

    		 GABA Receptor Neurological Disease
    Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine
  • HY-D1092
    DiBAC4(5)

    		Fluorescent Dye Neurological Disease
    DiBaC4(5) is a fluorescent voltage-sensitive dye that can be used to monitor the transmembrane potentials when Papain-dissociated retinal cells from adult zebrafish were exposed to GABAergic ligands. DiBaC4(5) is a potential-sensitive fluorescence dye .
    DiBAC4(5)
  • HY-172261
    YY-23

    		iGluR Neurological Disease
    YY-23 is a selective inhibitor of NMDAR (containing GluN2C or GluN2D). YY-23 inhibits GABAergic neurotransmission and enhances excitatory transmission by inhibiting NMDARs containing GluN2D on GABAergic interneurons in the prefrontal cortex. YY-23 has antidepressant activity and can be used for the research of neurological diseases .
    YY-23
  • HY-113316A
    (±)-Salsolinol hydrochloride

    		Endogenous Metabolite Opioid Receptor Neurological Disease
    (±)-Salsolinol hydrochloride is the hydrochloride form of (±)-Salsolinol (HY-113316). (±)-Salsolinol hydrochloride is a Dopamine (HY-B0451)-derived endogenous metabolite. (±)-Salsolinol hydrochloride activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (±)-Salsolinol hydrochloride
  • HY-W015050
    1-Anthramine

    1-Aminoanthracene

    		 GABA Receptor Chloride Channel Fluorescent Dye Neurological Disease
    1-Anthramine (1-aminoanthracene) is a fluorescent general anesthetic. potentiates GABAergic transmission with Kd = 0.1 mM, for binding to the general anesthetic site in horse spleen apoferritin (HSAF). 1-Anthramine fluorescence is enhanced when bound to HSAF. 1-Anthramine potentiates chloride currents elicited by GABA. 1-Anthramine can reversibly inhibit the movement of Xenopus laevis, with an EC50 value of 16 μM .
    1-Anthramine
  • HY-W004425
    DMPX

    3,7-Dimethyl-1-propargylxanthine

    		 Adenosine Receptor Neurological Disease
    DMPX (3,7-Dimethyl-1-propargylxanthine) is a selective A2A adenosine receptor (A2A AR) antagonist that crosses the blood-brain barrier, with a Ki of 11 μM for rat A2 adenosine receptor and a Ki of 45 μM for rat A1 adenosine receptor. By blocking A2A receptors in specific brain regions, DMPX protects dopaminergic and GABAergic neurons from mitochondrial dysfunction. DMPX is applicable to research related to depression, Parkinson's disease and Huntington's disease .
    DMPX
  • HY-B0122R
    Topiramate (Standard)

    McN 4853 (Standard); RWJ 17021 (Standard)

    		 Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate (Standard)
  • HY-P5183
    Hm1a

    		Sodium Channel Neurological Disease
    Hm1a is a venom peptide and a selective hNaV1.1 activator with an EC50 of 7.5 nM. Hm1a enhances hNaV1.1 and hNaV1.3 channel currents via delayed inactivation. Hm1a restores action potential firing in Dravet syndrome GABAergic inhibitory interneurons, reduces interictal epileptiform discharges and whole-brain hyperexcitability, lowers seizure frequency, and rescues premature death in Dravet syndrome mice. Hm1a can be used for the research of neurological disease, such as Dravet syndrome .
    Hm1a
  • HY-B0122S
    Topiramate-13C6

    McN 4853-13C6; RWJ 17021-13C6

    		 Isotope-Labeled Compounds Potassium Channel iGluR Sodium Channel GABA Receptor Carbonic Anhydrase Calcium Channel Neurological Disease
    Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate-13C6
  • HY-110234
    Topiramate D12

    McN 4853 D12 ; RWJ 17021 D12

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate D12
  • HY-139226
    GMQ

    2-Guanidine-4-methylquinazoline

    		 GABA Receptor Inflammation/Immunology
    GMQ is an acid-sensing ion channel modulator, competitive GABAAR antagonist. GMQ preferentially, potently, competitively inhibits GABAARs. GMQ inhibits α1β2, α1β2γ2, α4β2γ2 and α5β2γ2 GABAARs. GMQ enhances neuronal excitation through inhibition of GABAergic transmission. GMQ has anti-histamine effects in the enteric system, inhibiting gastric acid secretion .
    GMQ
  • HY-177573
    Cholesteryl γ-aminobutyrate

    		GABA Receptor Neurological Disease
    Cholesteryl γ-aminobutyrate is a γ-aminobutyric acid (GABA)-mimetic prodrug. Cholesteryl γ-aminobutyrate inhibits the orthodromically-evoked discharge of pyramidal cells in the CA1 region of the hippocampus. Cholesteryl γ-aminobutyrate suppresses the open-field activity of mice and rats in a dose-dependent manner and inhibits Bicuculline (HY-N0219)-induced seizures in mice. Cholesteryl γ-aminobutyrate can be used for the study of CNS diseases related to impaired GABAergic neuronal function .
    Cholesteryl γ-aminobutyrate
  • HY-P1426
    AmmTX3

    		Potassium Channel Neurological Disease
    AmmTX3 is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K + currents with a Ki of 131 nM. AmmTX3 induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 can be used in research related to pain, epilepsy, and autism spectrum disorder .
    AmmTX3
  • HY-123478
    Fengabine

    SL 79229

    		 GABA Receptor Neurological Disease
    Fengabine is a GABAergic antidepressant agent. Fengabine can be used for the research of depression .
    Fengabine
  • HY-169193
    Azocarnil

    		GABA Receptor Neurological Disease
    Azocarnil is a GABAergic agonist-potentiator. Azocarnil can be used in neurological research .
    Azocarnil
  • HY-171471
    SKF 10810

    		GABA Receptor Neurological Disease
    SKF 10810 is a GABAA receptor antagonist with an EC50 of 4.3 μM. By blocking GABAergic inhibition of the brain's reward pathways, SKF 10810 may exert antidepressant effects. SKF 10810 can be used for research in neurological disorders .
    SKF 10810
  • HY-114300
    DSP-0565

    		GABA Receptor Neurological Disease
    DSP-0565 (compound 17a) is a strong, broad-spectrum anti-epileptic agent (AED) candidate with unique GABAergic function. DSP-0565 shows anti-convulsant activity in various models (scPTZ, MES, 6 Hz and amygdala kindling) with good safety margin .
    DSP-0565
  • HY-B0122A
    Topiramate lithium

    McN 4853 lithium; RWJ 17021 lithium

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate lithium
  • HY-16579AS2
    Etifoxine-d5

    		GABA Receptor Neurological Disease
    Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine-d5
  • HY-16579AR
    Etifoxine (Standard)

    HOE 36-801 (Standard)

    		 Reference Standards GABA Receptor Neurological Disease
    Etifoxine (Standard) is the analytical standard of Etifoxine. This product is intended for research and analytical applications. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine (Standard)
  • HY-131885
    RuBi-Glutamate hexafluorophosphate sodium

    		GABA Receptor Neurological Disease
    RuBi-Glutamate hexafluorophosphate sodium is a neuronal activator. RuBi-Glutamate hexafluorophosphate sodium photocleaves to release glutamate upon one- or two-photon excitation, activating glutamate receptors in cortical pyramidal neurons. RuBi-Glutamate hexafluorophosphate sodium reduces peak amplitude of evoked GABAergic inhibitory postsynaptic currents in its caged form. RuBi-Glutamate hexafluorophosphate sodium can be used for the research of Huntington's disease .
    RuBi-Glutamate hexafluorophosphate sodium
  • HY-147736
    GABAA receptor agonist 2

    		GABA Receptor Neurological Disease
    GABAA receptor agonist 2 (compound 4c) is a potent GABAA receptor agonist. GABAA receptor agonist 2 shows anti-depression activities in classical mouse models of depression of FST and TST. GABAA receptor agonist 2 binds at the GABA binding site of GABAA receptor in order to produce GABAergic effects. GABAA receptor agonist 2 has the potential for the research of depression .
    GABAA receptor agonist 2
  • HY-B0122S1
    Topiramate-13C

    McN 4853-13C; RWJ 17021-13C

    		 Isotope-Labeled Compounds iGluR Potassium Channel Sodium Channel GABA Receptor Calcium Channel Carbonic Anhydrase Neurological Disease
    Topiramate- 13C (McN 4853- 13C) is 13C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate-13C
  • HY-147735
    GABAA receptor agonist 1

    		GABA Receptor Neurological Disease
    GABAA receptor agonist 1 (compound 3e) is a potent GABAA receptor agonist. GABAA receptor agonist 1 shows anti-depression activities in classical mouse models of depression of FST and TST. GABAA receptor agonist 1 binds at the GABA binding site of GABAA receptor in order to produce GABAergic effects. GABAA receptor agonist 1 has the potential for the research of depression .
    GABAA receptor agonist 1
  • HY-W013353
    (RS)-Salsolinol hydrobromide

    		Endogenous Metabolite Opioid Receptor Neurological Disease
    (RS)-Salsolinol hydrobromide is the hydrobromide form of (±)-Salsolinol (HY-113316). (RS)-Salsolinol hydrobromide is a Dopamine (HY-B0451)-derived endogenous metabolite. (RS)-Salsolinol hydrobromide activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (RS)-Salsolinol hydrobromide
  • HY-121299
    m-Chlorophenylbiguanide

    mCPBG

    		 5-HT Receptor Neurological Disease
    m-Chlorophenylbiguanide (mCPBG) is a potent high-affinity agonist of the 5-HT3 receptor, exhibiting an inhibitory effect on long-term potentiation (LTP) in the mossy fiber-CA3 system. mCPBG attenuates the magnitude of LTP at concentrations of 0.3-1 microM, demonstrating its role in modulating synaptic plasticity. Additionally, the impact of mCPBG on LTP is reversible by the GABAA receptor antagonist bicuculline, indicating a connection between its action and GABAergic neurotransmission.
    m-Chlorophenylbiguanide
  • HY-110234R
    Topiramate D12 (Standard)

    McN 4853 D12 (Standard); RWJ 17021 D12 (Standard)

    		 Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate D12 (Standard) is the analytical standard of Topiramate D12. This product is intended for research and analytical applications. Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate D12 (Standard)
  • HY-N9503
    Carvacryl acetate

    		TRP Channel Na+/K+ ATPase Parasite Others Neurological Disease Inflammation/Immunology
    Carvacryl acetate is an orally active and brain-penetrant TRPA1 receptor activator and Na +/K +-ATPase activator. Carvacryl acetate modulates GABAergic signaling, alters hippocampal GABA and glutamine levels, reduces lipid peroxidation and nitrite formation, scavenges hydroxyl radicals, and boosts glutathione and antioxidant enzyme activity. Carvacryl acetate inhibits Haemonchus contortus larval hatching, development, adult motility, and fecal egg counts, and induces adult worm structural damage. Carvacryl acetate can be used for the research of intestinal mucositis, gastrointestinal nematode infection, epilepsy, and neurodegenerative diseases .
    Carvacryl acetate
  • HY-P1426A
    AmmTX3 TFA

    		Potassium Channel Neurological Disease
    AmmTX3 TFA is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 TFA is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K + currents with a Ki of 131 nM. AmmTX3 TFA induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 TFA increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 TFA can be used in research related to pain, epilepsy, and autism spectrum disorder .
    AmmTX3 TFA
  • HY-Y0282
    Sodium bromide

    NSC 77384; Sanibrom 40

    		 Environmental Pollutants Neurological Disease
    Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
    Sodium bromide
  • HY-124057
    RO5126946

    		nAChR Neurological Disease
    RO5126946 is a selective, orally active α7 nAChR allosteric potentiator with EC50 values of 0.06 μM (hα7 nAChR) and 770 nM (α7 nAChR), and it crosses the blood-brain barrier. RO5126946 enhances synaptic transmission and positively modulates GABA-ergic responses by increasing peak current, slowing current decay, and elevating the frequency of spontaneous inhibitory postsynaptic currents, without affecting the recovery of receptors from the desensitized state. RO5126946 not only enhances subthreshold nicotine effects and improves associative learning, but also does not interfere with the original pro-cognitive effects of nicotine. RO5126946 can be used to study cognitive impairments associated with diseases such as Alzheimer's disease and schizophrenia .
    RO5126946
  • HY-167973
    GABA-palmitamide

    		GABA Receptor Neurological Disease
    GABA-palmitamide is a GABA-responsive compound. GABA-palmitamide exhibits a dose-dependent bidirectional regulatory effect on the stereotyped behavior induced by Apomorphine (HY-12723): high doses inhibit motor behavior, while low doses enhance stereotyped behaviors in the oral cavity. GABA-palmitamide can be used in research on behavior regulation .
    GABA-palmitamide
  • HY-179519
    Umbelopsisin A

    		GABA Receptor Reactive Oxygen Species (ROS) Neurological Disease
    Umbelopsisin A is a GABAA and GABAB non-selective agonist. Umbelopsisin A activates the GABAergic pathway, including notch signaling and fatty acid metabolism. Umbelopsisin A shows dual neuroprotection against glutamate excitotoxicity in vitro (reducing ROS and cell death) and in vivo. Umbelopsisin A can be used for the study of glaucoma and broader neurodegenerative disease applications .
    Umbelopsisin A
  • HY-16579R
    Etifoxine hydrochloride (Standard)

    HOE 36-801 hydrochloride (Standard)

    		 GABA Receptor Reference Standards Neurological Disease
    Etifoxine (hydrochloride) (Standard) is the analytical standard of Etifoxine (hydrochloride). This product is intended for research and analytical applications. Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine hydrochloride (Standard)
  • HY-185007
    LI-633

    		GABA Receptor Neurological Disease
    LI-633 is a selective and orally active GABAA receptor positive allosteric modulator (PAM) with a Ki of 21 nM. LI-633 produces robust potentiation of GABA-induced inward current, with EC50 values ranging from 8 nM (α5β2γ2) to 128 nM (α3β2γ2). LI-633 potentiates muscimol-induced GABAergic currents in rat dorsal root ganglion (DRG) neurons with an EC50 of 70.4 nM. LI-633 can be used for the study of visceral pain .
    LI-633
  • HY-182707
    JWX-A0108

    		nAChR Interleukin Related TNF Receptor NF-κB Neurological Disease
    JWX-A0108 is a selective human α7 nAChR positive allosteric modulator with an EC50 of 4.35 μM. JWX-A0108 potentiates α7 nAChR currents only in the presence of acetylcholine, with no direct activating effect or alteration of desensitization. JWX-A0108 enhances hippocampal GABAergic synaptic transmission by increasing spontaneous inhibitory postsynaptic currents. JWX-A0108 reduces the brain expression levels of IL-1β, TNF-α, and IL-6 by blocking the NF-κB signaling pathway, and reduces microglial activation by downregulating Iba1. JWX-A0108 effectively improves cognitive deficits, neuroinflammation, and hippocampal neuronal damage in mouse models of schizophrenia and Alzheimer's disease. JWX-A0108 can be used for research related to schizophrenia and Alzheimer's disease .
    JWX-A0108

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: